Payment overview · 2025
General Payments
$339.42
19 reported records · 11 companies
Healthcare provider profile · identity verified
Michael Ward Raybould, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NORTH KANSAS CITY, MO · NPI 1083686273
Verified facts
What the public records show
CMS Open Payments records show Michael Ward Raybould, MD received $339.42 in general payments during 2025 across 19 reported records.
ABBVIE INC. accounted for 17.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $57.97 | 17.1% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $48.83 | 14.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.41 | 10.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.95 | 9.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.27 | 9.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.09 | 8.6% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.80 | 7.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.26 | 6.8% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.89 | 5.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.77 | 5.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.18 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $339.42 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $57.97 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $57.97 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $48.83 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $35.41 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.95 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.95 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.80 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.26 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 144 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
33 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
44 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
168 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
144 | 25 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 651 | 170 |
| Amlodipine Besylate | Amlodipine Besylate | 542 | 138 |
| Levothyroxine Sodium | Levothyroxine Sodium | 474 | 124 |
| Losartan Potassium | Losartan Potassium | 380 | 102 |
| Gabapentin | Gabapentin | 361 | 79 |
| Metformin Hcl | Metformin Hcl | 360 | 96 |
| Omeprazole | Omeprazole | 347 | 93 |
| Lisinopril | Lisinopril | 345 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 309 | 78 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 277 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 276 | 76 |
| Potassium Chloride | Potassium Chloride | 272 | 78 |
| Furosemide | Furosemide | 255 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 251 | 59 |
| Allopurinol | Allopurinol | 228 | 59 |
| Simvastatin | Simvastatin | 222 | 56 |
| Tramadol Hcl | Tramadol Hcl | 214 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 196 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 192 | 46 |
| Jardiance | Empagliflozin | 168 | 29 |
| Meloxicam | Meloxicam | 164 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 162 | 42 |
| Alprazolam | Alprazolam | 148 | 32 |
| Carvedilol | Carvedilol | 144 | 43 |
| Ozempic | Semaglutide | 144 | 25 |
| Trazodone Hcl | Trazodone Hcl | 144 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 135 | 30 |
| Paroxetine Hcl | Paroxetine Hcl | 129 | 28 |
| Lorazepam | Lorazepam | 125 | 29 |
| Eliquis | Apixaban | 124 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 123 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 120 | 21 |
| Azithromycin | Azithromycin | 119 | 89 |
| Clopidogrel | Clopidogrel Bisulfate | 117 | 26 |
| Montelukast Sodium | Montelukast Sodium | 108 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 106 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 40 |
| Sertraline Hcl | Sertraline Hcl | 95 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 90 | 27 |
| Famotidine | Famotidine | 89 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 87 | 22 |
| Alendronate Sodium | Alendronate Sodium | 86 | 17 |
| Clonazepam | Clonazepam | 79 | 13 |
| Donepezil Hcl | Donepezil Hcl | 75 | 21 |
| Glipizide | Glipizide | 70 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | suppressed |
| Methylprednisolone | Methylprednisolone | 69 | 50 |
| Ondansetron Odt | Ondansetron | 69 | 26 |
| Warfarin Sodium | Warfarin Sodium | 69 | 17 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 68 | 68 |
| Glimepiride | Glimepiride | 68 | 17 |
| Atenolol | Atenolol | 67 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 18 |
| Spironolactone | Spironolactone | 66 | 16 |
| Prednisone | Prednisone | 62 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 18 |
| Estradiol | Estradiol | 58 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 58 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 16 |
| Chlorthalidone | Chlorthalidone | 57 | 15 |
| Ezetimibe | Ezetimibe | 57 | 13 |
| Celecoxib | Celecoxib | 56 | 18 |
| Finasteride | Finasteride | 56 | 15 |
| Fenofibrate | Fenofibrate | 55 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 31 |
| Clonidine Hcl | Clonidine Hcl | 53 | 11 |
| Farxiga | Dapagliflozin Propanediol | 53 | suppressed |
| Mounjaro | Tirzepatide | 53 | suppressed |
| Cephalexin | Cephalexin | 52 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 49 | 35 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 47 | 12 |
| Fluconazole | Fluconazole | 47 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 45 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 32 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 44 | 36 |
| Diazepam | Diazepam | 43 | 11 |
| Methocarbamol | Methocarbamol | 43 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | 13 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 42 | 12 |
| Synthroid | Levothyroxine Sodium | 41 | 11 |
| Amoxicillin | Amoxicillin | 38 | 28 |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Nystatin | Nystatin | 38 | 19 |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Pregabalin | Pregabalin | 37 | 11 |
| Temazepam | Temazepam | 37 | suppressed |
| Valsartan | Valsartan | 37 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 36 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 36 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | 11 |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 33 | 32 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | 11 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Digoxin | Digoxin | 32 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 28 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 24 | 23 |
| Colestipol Hcl | Colestipol Hcl | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Testosterone | Testosterone | 20 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 19 |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Ascomp With Codeine | Codeine/Butalbital/Asa/Caffein | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 12 |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | 11 |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Opium Tincture | Opium Tincture | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $339.42 · 19 records | ABBVIE INC. | EVENITY, FARXIGA, GEMTESA, LEQVIO, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, Veozah, YUPELRI, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error